Replies to post #503780 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Two Other Eventual Share Price Factors

Stocanalytics's new AVXL share price projections (in 3 to 5 yrs):

Europe Only : $308 to $715 share price (to $913 in ideal conditions)
Europe + US : over $1000 ($1100 to $1859)

I note, however, that none of these metrics involve any blarcamesine sales for prophylactic (disease prevention or delay) therapies. Merely for Alzheimer's treatments, in the U.S. and the EU.

Two additional purposes for which blarcamesine will be prescribed:

1. The Anavex Alzheimer's delay or prevention factor. On the basis of the several Alzheimer's vulnerability tests blarcamesine will be prescribed prodromally, before any frank or obvious Alzheimer's symptoms are observed. With these prophylactic therapies Alzheimer's in vulnerable patient populations will be at least greatly delayed, if not altogether obviated.

2. The Anavex anti-aging factor. It will be discovered that people taking blarcamesine simply do not age as quickly or severely. Eventually, blarcamesine (or, Anavex 3-71) will be commonly prescribed widely to adults in their 40s or 50s, thereby facilitating good general health in their geriatric years.

With Nos. 1 and 2 Stocanalytics's AVXL share price projections can be doubled.

[mike_dotcom]

Nah, they'll just double down.